angiotensin ii (3-7) has been researched along with cardiovascular agents in 1 studies
| Studies (angiotensin ii (3-7)) | Trials (angiotensin ii (3-7)) | Recent Studies (post-2010) (angiotensin ii (3-7)) | Studies (cardiovascular agents) | Trials (cardiovascular agents) | Recent Studies (post-2010) (cardiovascular agents) |
|---|---|---|---|---|---|
| 15 | 0 | 1 | 17,645 | 1,480 | 6,891 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, A; Shang, Z; Zhang, Y | 1 |
1 other study(ies) available for angiotensin ii (3-7) and cardiovascular agents
| Article | Year |
|---|---|
Angiotensin-(3-7) alleviates isoprenaline-induced cardiac remodeling via attenuating cAMP-PKA and PI3K/Akt signaling pathways.
Topics: Angiotensin II; Animals; Cardiomegaly; Cardiovascular Agents; Cells, Cultured; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Fibrosis; Isoproterenol; Male; Mice, Inbred C57BL; Myocytes, Cardiac; Peptide Fragments; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; Signal Transduction; Ventricular Remodeling | 2021 |